NASDAQ:ACHN Achillion Pharmaceuticals (ACHN) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.01▼$1.0150-Day Range$6.76▼$6.7652-Week Range$2.06▼$7.01VolumeN/AAverage Volume8.44 million shsMarket Capitalization$141.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Achillion Pharmaceuticals (NASDAQ:ACHN) StockAchillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.Read More ACHN Stock News HeadlinesMay 20, 2023 | fool.comLexicon Pharmaceuticals (NASDAQ: LXRX)February 19, 2023 | thestreet.comGilead Sciences Buying Achillion Was Twitter Speculation at Its FinestSeptember 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 18, 2022 | investing.comACHN_old Historical DataJanuary 13, 2022 | thestreet.comWhy Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading TodayJanuary 12, 2022 | thestreet.comJim Cramer's 'Mad Money' Recap: Here's Next Week's Game PlanApril 14, 2021 | investing.comXunlei Ltd Adr (XNET)April 14, 2021 | investing.comG1 Therapeutics Inc (GTHX)September 24, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.July 7, 2020 | www.bloomberg.comAchillion Announces Pricing of Secondary Offering Of Common StockJune 7, 2020 | www.bloomberg.comAchillion Reports First Quarter 2018 Financial Results and Management TransitionJune 2, 2020 | www.bloomberg.comLifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central EuropeanMay 26, 2020 | www.bloomberg.comAchillion Appoints Nicholas Simon to Board of DirectorsMarch 22, 2020 | www.fool.comAchillion Pharmaceuticals (ACHN) - Options ChainFebruary 3, 2020 | seekingalpha.comAlexion Pharmaceuticals Is On SaleJanuary 27, 2020 | seekingalpha.comAchillion up 16% premarket on advancement of Alexion tie-upJanuary 27, 2020 | www.benzinga.com14 Biotechnology Stocks Moving In Monday's Pre-Market SessionJanuary 8, 2020 | finance.yahoo.comApellis' (APLS) PNH Drug Betters Alexion's Soliris in StudyJanuary 8, 2020 | finance.yahoo.comApellis' (APLS) PNH Drug Betters Alexion's Soliris in StudyDecember 19, 2019 | seekingalpha.comAchillion shareholders back Alexion takeoverDecember 9, 2019 | finance.yahoo.comDid Hedge Funds Drop The Ball On Achillion Pharmaceuticals, Inc. (ACHN) ?December 9, 2019 | finance.yahoo.comAchillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology MeetingNovember 30, 2019 | www.benzinga.comRigrodsky & Long, P.A. Files Class Action Suit Against Achillion Pharmaceuticals, Inc.November 20, 2019 | finance.yahoo.comAchillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNHNovember 11, 2019 | finance.yahoo.comAchillion Announces Clearance of Investigational New Drug Application for ACH-5228November 7, 2019 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Continues Legal Inquiry Regarding the BuyoutNovember 7, 2019 | seekingalpha.comAchillion Pharmaceuticals EPS beats by $0.02See More Headlines Receive ACHN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achillion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACHN Company Calendar Last Earnings11/07/2019Today9/24/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ACHN CUSIP00448Q20 CIK1070336 Webwww.achillion.com Phone203-624-7000FaxN/AEmployees56Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.95% Return on Assets-29.09% Debt Debt-to-Equity Ratio0.01 Current Ratio8.96 Quick Ratio8.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book0.53Miscellaneous Outstanding Shares140,047,000Free FloatN/AMarket Cap$141.45 million OptionableOptionable Beta1.59 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Joseph Truitt (Age 54)Pres, CEO & Director Ms. Martha E. Manning (Age 64)Exec. VP, Gen. Counsel & Corp. Sec. Mr. Brian R. Di Donato (Age 52)CFO, SVP & Treasurer Mr. Paul Firuta (Age 53)Exec. VP & COO Dr. Kevin P. MalobiskySr. VP of Regulatory Affairs, Quality & ComplianceKey CompetitorsMerrimack PharmaceuticalsNASDAQ:MACKXOMANASDAQ:XOMARigel PharmaceuticalsNASDAQ:RIGLEmergent BioSolutionsNYSE:EBSFortress BiotechNASDAQ:FBIOView All Competitors ACHN Stock - Frequently Asked Questions How were Achillion Pharmaceuticals' earnings last quarter? Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) issued its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. What other stocks do shareholders of Achillion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Iconix Brand Group (ICON), Celldex Therapeutics (CLDX) and Edap Tms (EDAP). What is Achillion Pharmaceuticals' stock symbol? Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN." What is Achillion Pharmaceuticals' stock price today? One share of ACHN stock can currently be purchased for approximately $1.01. How much money does Achillion Pharmaceuticals make? Achillion Pharmaceuticals (NASDAQ:ACHN) has a market capitalization of $141.45 million. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. How can I contact Achillion Pharmaceuticals? Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The official website for the company is www.achillion.com. The biopharmaceutical company can be reached via phone at 203-624-7000. This page (NASDAQ:ACHN) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achillion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.